TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7933844
Drug: Constant infusion
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant infusion method
Study: 11429362
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection technique
Study: 31339232
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker
Study: 27032074
Drug: All antihypertensive
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All antihypertensive medications
Study: 23085706
Drug: Ultrasonography-guided injection
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonography-guided injection
Study: 18672254
Drug: Second IVIG
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second IVIG infusion (2 g/kg)
Study: 16164708
Drug: Alefacept plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alefacept plus UVB treatment (6-week and 12-week)
Study: 16164708
Drug: Alefacept monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alefacept monotherapy
Study: 16164708
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (alefacept/UVB)
Study: 12858653
Drug: Memantine 10
Normalized name: Memantine 10mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine 10 mg twice daily for up to 28 weeks
Study: 12858653
Drug: Memantine 10
Normalized name: Memantine 10mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine 10 mg twice daily
Study: 10371538
Drug: Topiramate (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (titrated to approximately 6 mg/kg/d)
Study: 8898424
Drug: Recombinant interferon-alpha
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recombinant interferon-alpha 2a therapy for 26 weeks
Study: 6295596
Drug: VP-16 (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: VP-16 (180 mg/m2 on 3 consecutive days at 2 weekly intervals)
Study: 22394471
Drug: Org 25935
Normalized name: ORG-25935
DrugBank: ORG-25935 (DB12220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 25935 (4 mg)
Study: 20079620
Drug: Injecting drugs
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injecting drugs (general)
Study: 16277632
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg rapid-release nicotine gum (RRNG)
Study: 16277632
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg nicotine polacrilex gum (NPG)
Study: 12804864
Drug: Ventrogluteal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventrogluteal injection of DTPw vaccine
Study: 12804864
Drug: Ventrogluteal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventrogluteal injection of DTPa vaccine
Study: 12804864
Drug: Ventrogluteal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventrogluteal injection of HibTITER vaccine
Study: 12804864
Drug: Ventrogluteal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventrogluteal injection
Study: 12804864
Drug: Anterolateral thigh
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anterolateral thigh injection
Study: 10605191
Drug: Triple combinations
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combinations including two nucleoside analogues and a potent protease inhibitor
Study: 10605191
Drug: Protease inhibitors
Normalized name: Protease inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitors and triple therapy
Study: 8947337
Drug: Nasal allergen
Normalized name: catfish allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal allergen challenges after 4 years' immunotherapy
Study: 6755307
Drug: Basic therapy
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic therapy + calcitonin
Study: 6755307
Drug: Basic therapy
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic therapy + calcifediol
Study: 29069568
Drug: Medical-therapy group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical-therapy group (n=59)
Study: 21971755
Drug: Electrostimulation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrostimulation treatment protocol (30 sessions starting four days post-operation)
Study: 10853696
Drug: Acute submaximal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute submaximal exercise with NO inhalation (mask)
Study: 10853696
Drug: Acute submaximal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute submaximal exercise without NO inhalation (no mask)
Study: 1325076
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin CY 216 (Fraxiparine) in a fixed dose
Study: 1325076
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) in doses adjusted according to the activated partial thromboplastin time
Study: 6465619
Drug: Pentoxifylline (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (1200 mg/day, Trental 400 tds.)
Study: 6465619
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid and dipyridamole (1050 mg + 150 mg/day)
Study: 29329305
Drug: TDF monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF monotherapy (n = 111)
Study: 29329305
Drug: LAM+ADV combination
Normalized name: Viril Lam
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAM+ADV combination therapy (n = 58)
Study: 29329305
Drug: TDF monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF monotherapy (n = 111) with cirrhosis
Study: 26823540
Drug: Monovalent rotavirus
Normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent rotavirus vaccine (2 doses)
Study: 26823540
Drug: Mixed vaccine
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed vaccine schedules (3 doses)
Study: 26823540
Drug: Single vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single vaccine reference groups (2 doses)
Study: 22285609
Drug: multicomponent cognitive‐behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: multicomponent cognitive‐behavioral therapy (CBT)
Study: 22285609
Drug: multicomponent cognitive‐behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: multicomponent cognitive‐behavioral therapy (CBT) with hypnosis
Study: 22285609
Drug: standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard care (pharmacological treatment)
Study: 17202433
Drug: Individualized dietary
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized dietary modification + recombinant human growth hormone (GH) (0.1 mg/kg daily x 21 days, then 3 times/week)
Study: 9791525
Drug: Intensified education
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified education through a booklet about amblyopia and its treatment.
Study: 7702027
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g fish-oil concentrate/d (approximately 3.4 g eicosapentaenoic and docosahexaenoic acids/d)
Study: 7702027
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g fish-oil concentrate/d
Study: 27530310
Drug: IVIG 1
Normalized name: Intravenous immunoglobulin (IVIg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG 1 g/kg/day for two consecutive days
Study: 27530310
Drug: PLEX 1-L
Normalized name: Kleer Plex
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLEX 1-L plasma exchange five times with 5% albumin replacement fluid, every other day, 10-30 days before the procedure
Study: 16205904
Drug: Pregabalin fixed
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin fixed dose treatment
Study: 16205904
Drug: Pregabalin flexible
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin flexible dose treatment
Study: 15456623
Drug: Immunotherapy administered
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy administered in the initiation phase according to a cluster schedule of eight doses injected on four visits.
Study: 15456623
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no immunotherapy).
Study: 9237962
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of 2.1 mg d‐alpha‐tocopheryl acetate and 0.06 microg ergocalciferol per gram of olestra
Study: 9237962
Drug: Olestra (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olestra (all doses)
Study: 8233263
Drug: Ear, hand,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ear, hand, and foot reflexology treatment
Study: 3317354
Drug: Recombinant yeast‐derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant yeast‐derived hepatitis B vaccine (3 doses of 40 micrograms) administered at 0, 1, 2 months
Study: 3317354
Drug: Recombinant yeast‐derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant yeast‐derived hepatitis B vaccine (3 doses of 40 micrograms) administered at 0, 1, 6 months
Study: 27225988
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy only (no stenting)
Study: 23996068
Drug: BPTB reconstruction
Normalized name: CONSTRICTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPTB reconstruction with synthetic degradable augmentation device
Study: 23996068
Drug: BPTB reconstruction
Normalized name: CONSTRICTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPTB reconstruction without augmentation
Study: 23996068
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (with and without augmentation)
Study: 23451449
Drug: Plygersic gel
Normalized name: acetaminophen / hydrocodone bitartrate Oral Capsule [Polygesic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plygersic gel (4% ginger and plai extract)
Study: 23451449
Drug: 1% Diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% Diclofenac gel
Study: 18318721
Drug: Intense Pulsed
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense Pulsed Light (IPL) - 560-nm filter, 30 J/cm², 2.4/4.0-ms pulse with 10-ms delay, three treatments spaced 1 month apart
Study: 18318721
Drug: Er:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er:YAG laser - 3.8 J/cm², 30% pattern overlap, 0% interpulse overlap, 15 microm per pass, three treatments spaced 1 month apart
Study: 10482323
Drug: Three hourly
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three hourly nebulized salbutamol
Study: 10482323
Drug: Four hourly
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four hourly nebulized salbutamol
Study: 1751998
Drug: Metoclopramide 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 0.15 mg.kg‐1
Study: 7141758
Drug: Fortimicin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortimicin A 2.5 mg/kg
Study: 7141758
Drug: Fortimicin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortimicin A 5.0 mg/kg
Study: 7141758
Drug: Fortimicin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortimicin A 7.5 mg/kg
Study: 25256892
Drug: Whole body
Normalized name: MaxiVision Whole Body Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole body hyperthermia treatment at 38.7-39°C for 60 minutes
Study: 25256892
Drug: Whole body
Normalized name: MaxiVision Whole Body Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole body hyperthermia treatment
Study: 20093825
Drug: Renal progenitor/stem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal progenitor/stem cell therapy
Study: 18059593
Drug: Carbohydrate supplementation
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate supplementation (1 g.kg(‐1).d(‐1))
Study: 18059593
Drug: Glutamine supplementation
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine supplementation (70 mg.kg(‐1).d(‐1))
Study: 18059593
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of carbohydrate and glutamine supplementation
Study: 10028374
Drug: New slow
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: New slow release tablet formulation (Pindac) 12.5 mg every 12 h for 7 days
Study: 10028374
Drug: Standard slow
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard slow release capsule formulation 12.5 mg every 12 h for 7 days
Study: 7672764
Drug: Liver resection
Normalized name: LIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liver resection combined with post-operative locoregional immunotherapy + chemotherapy (Group B)
Study: 2285086
Drug: Bone-patellar tendon-bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone-patellar tendon-bone augmentation
Study: 2285086
Drug: Kennedy Ligament
Normalized name: human ligament preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kennedy Ligament Augmentation Device
Study: 7178370
Drug: Metaclazepam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metaclazepam (10 mg p.o. and 30 mg p.o.)
Study: 30143879
Drug: Very thin-strut
Normalized name: Primula veris extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very thin-strut biodegradable polymer drug-eluting stents (BP-DES)
Study: 30143879
Drug: Thin-strut durable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thin-strut durable polymer drug-eluting stents (DP-DES)
Study: 25899926
Drug: 1g of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1g of acetaminophen twice daily for 12 weeks
Study: 24525393
Drug: Placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily for 12 weeks
Study: 16682403
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (0.5 mg buserelin)
Study: 12791434
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg memantine/day
Study: 9315417
Drug: Contraceptive vaginal
Normalized name: VCF 4% Contraceptive Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraceptive vaginal film containing 19 mg BZK
Study: 9315417
Drug: Contraceptive vaginal
Normalized name: VCF 4% Contraceptive Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraceptive vaginal film containing 25 mg BZK
Study: 9315417
Drug: VCF containing
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VCF containing 70 mg N‐9
Study: 1586375
Drug: Preparation A
Normalized name: POVIDONE-IODINE 75 mg in 1 mL TOPICAL SOLUTION [Antiseptic Patient Preoperative Skin Preparation and Surgical Hand Scrub]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation A (40 mg slow-release isosorbide mononitrate)
Study: 1586375
Drug: Preparation B
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation B (40 mg slow-release isosorbide mononitrate)
Study: 1586375
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation C (40 mg slow-release isosorbide mononitrate)
Study: 3991283
Drug: Preventive care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive care treatment episodes
Study: 20543706
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy initiated a median of 7 weeks before delivery (cohort A)
Study: 20543706
Drug: Zidovudine from
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine from 34 to 36 weeks gestation until delivery with single-dose nevirapine in labor (cohort B)
Study: 15957509
Drug: Valacyclovir (3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir (3000 mg/day)
Study: 2062621
Drug: HbOC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HbOC vaccine (three doses at 2, 4, and 6 months of age)
Study: 2062621
Drug: HbOC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HbOC vaccine (two doses)
Study: 2062621
Drug: HbOC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HbOC vaccine (one dose)
Study: 6203496
Drug: Different antidepressant
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different antidepressant treatments
Study: 25282871
Drug: 12-week self-administered
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week self-administered weight lifting program
Study: 22780937
Drug: Nimotuzumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimotuzumab (200 mg per week for 6 weeks), palitaxel liposome 160 mg/m2, and carboplatin (AUC = 6)
Study: 15984909
Drug: Trimetazidine 20mg
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine 20mg three times daily
Study: 11776548
Drug: Oxygen-conserving nasal
Normalized name: TUBE,NASAL OXYGEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen-conserving nasal cannula (CNC) at 0.5 L/min
Study: 11776548
Drug: Oxygen-conserving nasal
Normalized name: TUBE,NASAL OXYGEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen-conserving nasal cannula (CNC) at 1.0 L/min
Study: 11776548
Drug: Oxygen-conserving nasal
Normalized name: TUBE,NASAL OXYGEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen-conserving nasal cannula (CNC) at 1.5 L/min
Study: 11776548
Drug: Oxygen-conserving nasal
Normalized name: TUBE,NASAL OXYGEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen-conserving nasal cannula (CNC) at 2.0 L/min
Study: 6839666
Drug: Control conditions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control conditions (without drugs)
Study: 29254367
Drug: Group intervention
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group intervention program (four weekly sessions)
Study: 28721992
Drug: Intra-pocket 20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-pocket 20% benzocaine gel
Study: 21423021
Drug: Genotype-informed dosing
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotype-informed dosing algorithms
Study: 21423021
Drug: Clinical dosing
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical dosing algorithms
Study: 16341856
Drug: LI 160
Normalized name: LIS-1
DrugBank: LIS-1 (DB18388)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LI 160 (HYF 41 mg/day)
Study: 16341856
Drug: SJW powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: SJW powder tablets 2.7 g/day (HYF 12 mg/day)
Study: 16341856
Drug: SJW powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: SJW powder tablets 2.7 g/day (HYF 0.13 mg/day)
Study: 1090796
Drug: Topical nitrogen
Normalized name: nitrogen Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nitrogen mustard
Study: 6661512
Drug: Propranolol hydrochloride
Normalized name: Propranolol Hydrochloride
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol hydrochloride (2 X 40 mg)
Study: 12355570
Drug: Lidocaine preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine preparations with laser assistance
Study: 7528712
Drug: FK506 (Tacrolimus)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FK506 (Tacrolimus) treatment without cellular rejection
Study: 7528712
Drug: FK506 (Tacrolimus)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FK506 (Tacrolimus) treatment with cellular rejection
Study: 2168586
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1200 mg daily)
Study: 6159865
Drug: Clomipramine hydrochloride
Normalized name: Clomipramine Hydrochloride
DrugBank: Clomipramine (DB01242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomipramine hydrochloride treatment for 3 weeks
Study: 30729346
Drug: Supragingival debridement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supragingival debridement (SD) with adjunctive full mouth glycine powder air polishing (FM‐GPAP) (test, n = 42)
Study: 19375250
Drug: Valproate treatment
Normalized name: valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproate treatment (1500 mg/day by Day 6)
Study: 17525387
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant tissue plasminogen activator (rt-PA) started at 0.6 mg/kg over 30 minutes, followed by additional rt-PA via EKOS micro-infusion catheter or standard microcatheter up to a total dose of 22 mg over 2 hours.
Study: 17525387
Drug: Combined intravenous
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intravenous and intra-arterial approach
Study: 2190927
Drug: 1.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 mg/kg quotid. enalkiren
Study: 2190927
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg q.i.d. enalkiren
Study: 27828
Drug: Control (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (placebo or no treatment not explicitly mentioned)